Argotec unveils HAWK Plus, its modular platform for microsatellites up to 130kg, at the Satellite Conference & Exhibition ...
The Clarity-1 very-low Earth orbit (VLEO) imaging satellite by Denver's Albedo Space and the first microsatellite owned and ...
The NCI will lead the trial of the firm's Versamune MUC1 immunotherapy and its antibody-drug conjugate PDS01ADC.
The Hearty Soul on MSN5d
Rectal Cancer Vanishes After Immunotherapy Trial, Now Classified as FDA Breakthrough TherapyA humble yet groundbreaking clinical trial at Memorial Sloan Kettering Cancer Center (MSK) has achieved unprecedented results ...
Phase 1/2 trial evaluating the proprietary combination to be run under CRADA with the National Cancer InstituteSecondVersamune®platform candidate ...
This €1.6 Million financing will allow MSInsight to finalize MSIcare's technological development, demonstrate its performance ...
When Vanessa was diagnosed with advanced colon cancer in 2014, just before her 60th birthday, the mother and grandmother learned the cancer had ...
Marwan G. Fakih, MD, discusses the next steps for the clinical development of the balstilimab plus botensilimab in ...
For Colorectal Cancer Awareness Month, Scott Kopetz, MD, PhD, FACP, discussed the BREAKWATER trial in metastatic BRAF ...
Bristol Myers Squibb Opdivo global programme lead and vice-president Dana Walker stated: “Today’s milestone brings us one step closer to providing an effective dual immunotherapy treatment option to ...
The FDA accepted Bristol Myers' sBLA for Opdivo plus Yervoy as a first-line treatment for MSI-H/dMMR metastatic colorectal cancer. The submission, backed by Phase 3 CheckMate -8HW data, received ...
INTRODUCTION: Immunotherapy outcomes have been underwhelming in most gastrointestinal malignancies. Microsatellite instable (MSI-H) colorectal cancers (CRC) are an exception. Immune checkpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback